Tag: leukemia

En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie¹

En attendant la décision finale de la Commission européenne, le régime offre une nouvelle norme de soins pour les patients éligibles atteints d’LMC^1,2

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

Les résultats d’études croisées de l’association ibrutinib et vénétoclax en première intention montrent un bénéfice clinique significatif pour une durée fixe, ainsi qu’une probabilité accrue de maladie résiduelle minimale indétectable et de survie sans progression par rapport à l’association acalabrutinib et vénétoclax¹

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹ 

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities